Follow Slashdot blog updates by subscribing to our blog RSS feed

 



Forgot your password?
typodupeerror
×

Comment Re:Does anybody still "upgrade"? (Score 1) 222

With Win 7 upgrade they took the fresh install option away at one point, though I don't know if they've since restored it. Well, it would install fine but the upgrade license wouldn't activate unless you went in to the registry to changed the id to having been an upgrade install.

I get upgrade copies of windows from my University for like $8. I have a CD binder with Win XP (no sp, sp1, sp2, sp3, x64), Vista, Win7 (x32, x64). That includes multiple copies of some where I had friends pick them up.

Comment The real use for this technology (Score 1) 22

Summary and TFA seem to skim over the main area where this technology will likely see application--in looking at drug permeability and transport across the intestinal membrane. This is something that gets examined for EVERY orally administered drug and right now this is done primarily with cell culture monolayers of intestinal cells. This model allows for the addition of peristaltic forces and other stressors to give a more physiologically relevant system.

Comment Re:My money is on him winning that science fair. n (Score 3, Interesting) 236

You clearly misunderstood the post you're responding to, or are yourself, an

Idiot.

The poster implied that he would sell the rights to a pharma company and indeed licensing compounds from smaller companies/research labs is indeed standard practice. If you meant that the pharma companies don't have enough new drugs of their own, this is in fact wrong.

The second part of the post implied the kid would never be heard from again. If he made enough money it's possible. I'm guessing you misinterpreted this as a statement the company would buy his compound and it would never see the light of day, thus garnering your idiot comment. While it's not what he meant, it is in fact also common practice in pharma for companies to license the rights to compounds similar to those they are developing just to eliminate potential competition. It's why often when licensing a compound stipulations are added that the purchasing company must intend to develop it.

All of this is likely moot as the kid does not own the rights to the compounds. TFA doesn't specify whether they are novel but my guess would be he worked with a library of existing compounds that showed some activity against cystic fibrosis in preliminary screenings.

Comment Warfarin (Score 2) 151

One of the problems with warfarin is that there is a lot of variability between patients. The main clearance enzyme for warfarin, CYP2C9, has reduced function in around roughly 25% of patients due to genetic polymorphisms. The target for warfarin, VKORC1, is highly variable due to genetics and the substrate concentrations, vitamin K, can vary greatly with dietary intake. Warfarin also has a narrow therapeutic window. If concentrations are too high there can be bleeding problems and at concentrations too low it's ineffective.

The end result is that the initial warfarin dosing can be extremely variable and requires close therapeutic monitoring when starting a new patient on the treatment. It's a far cry from something like aspirin where there is a pretty good idea of what dose a patient will need. A drug company producing something similar to warfarin that wasn't subject to such high genetic variability would be clinically preferred due to lower health care costs in starting treatment on new patients. That said, when you're properly dosed warfarin is pretty damn effective.

Slashdot Top Deals

One man's constant is another man's variable. -- A.J. Perlis

Working...